Learn More-External Link
Trending at Lumira Ventures
Pharmasset’s Hepatitis C Drug Has A Promising Future
Learn More-External Link
Natus Medical to Acquire Excel-Tech Ltd.
Learn More-External Link
Pharmasset Accesses up to $30 Million of Working Capital
Learn More-External Link
Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
Learn More-External Link
Argos Therapeutics’ Scientific Founder Ralph Steinman, M.D., Receives…
Learn More-External Link
Replidyne’s Investigational Antibacterial Agent REP3123 Prevents Toxin Production…
Learn More-External Link
MAKO Surgical Announces Filing Of Registration Statement With SEC For IPO
Learn More-External Link
MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors
Learn More-External Link
MDS Capital Corp. announces investment team promotions and changes its name to Lumira Capital Corp.
MDS Capital Corp., one of North America’s oldest venture capital firms targeting health and life science investments, announced today key management promotions and that, effective immediately, it will be changing its name to Lumira Capital Corp. The management changes include: …
Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
Learn More-External Link
Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Learn More-External Link
R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Learn More-External Link
Replidyne Pipeline Featured at 47th Annual Interscience Conference on …
Learn More-External Link
R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Learn More-External Link